Skip to main content
SpringerLink
Log in

The Diagnostic Approach to the Febrile Neutropenic Patient: Clinical Considerations

  • Chapter
  • First Online:
Infections in Hematology

Abstract

There are several important factors to be considered by the clinician who is assessing a cancer patient with the presentation of a possible neutropenic fever syndrome. Such considerations can help the clinician to ascertain the likelihood of infection and identify the likelihood that the patient will develop serious medical complications as a function of the febrile neutropenic episode. A high clinical index of suspicion in the context of cancer patients who are receiving systemic cytotoxic therapy and who present with a febrile illness between day 10 and 14 of the current chemotherapy cycle is an important part of the initial assessment. An understanding that initial signs and symptoms of infection may be muted by the relative lack of circulating inflammatory cells. Inappropriate initial management remains associated with unacceptably high excess morbidity and mortality. A rapid systematic assessment is critical for the choice of empirical antibacterial therapy, the formulation and venue for the administration of that therapy, and timeliness of the administration of treatment. Standards have been developed for these assessments and interventions and have been recommended as important measures of system performance.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006;42:2433–53.

    CAS  PubMed  Google Scholar 

  2. Ahn S, Lee YS, Chun YH, et al. Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia. Support Care Cancer. 2011;19(8):1151–8.

    Google Scholar 

  3. Amado VM, Vilela GP, Queiroz Jr A, Amaral AC. Effect of a quality improvement intervention to decrease delays in antibiotic delivery in pediatric febrile neutropenia: a pilot study. J Crit Care. 2011;26(1):103.e9–12.

    Google Scholar 

  4. Amoateng-Adjepong Y, Del Mundo J, Manthous CA. Accuracy of an infrared tympanic thermometer. Chest. 1999;115:1002–5.

    CAS  PubMed  Google Scholar 

  5. Andre S, Taboulet P, Elie C, Milpied N, Nahon M, Kierzek G, Billemont M, Perruche F, Charpentier S, Clement H, Pourriat JL, Claessens YE. Febrile neutropenia in French emergency departments: results of a prospective multicentre survey. Crit Care. 2010;14:R68.

    PubMed Central  PubMed  Google Scholar 

  6. Baden LR, Bensinger W, Angarone M, et al. NCCN Guidelines Version 2. Prevention and treatment of cancer-related infections. 2014. Available at: http://www.nccn.org/professionals/physician_gls/pdf/infections.pdf. Accessed 23 Aug 2014.

  7. Baskaran ND, Gan GG, Adeeba K. Applying the multinational association for supportive care in cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients. Ann hematolo. 2008;87(7):563–9.

    Google Scholar 

  8. Blay JY, Chauvin F, Le Cesne A, Anglaret B, Bouhour D, Lasset C, Freyer G, Philip T, Biron P. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol. 1996;14:636–43.

    CAS  PubMed  Google Scholar 

  9. Blijlevens N, Schwenkglenks M, Bacon P, D’Addio A, Einsele H, Maertens J, Niederwieser D, Rabitsch W, Roosaar A, Ruutu T, Schouten H, Stone R, Vokurka S, Quinn B, McCann S. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy–European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol. 2008;26:1519–25.

    CAS  PubMed  Google Scholar 

  10. Blijlevens NM, Donnelly JP, De Pauw BE. Impaired gut function as risk factor for invasive candidiasis in neutropenic patients. Br J Haematol. 2002;117:259–64.

    PubMed  Google Scholar 

  11. Blijlevens NM, van’t Land B, Donnelly JP, M’Rabet L, de Pauw BE. Measuring mucosal damage induced by cytotoxic therapy. Support Care Cancer. 2004;12:227–33.

    CAS  PubMed  Google Scholar 

  12. Bochud PY, Eggiman P, Calandra T, Van Melle G, Saghafi L, Francioli P. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis. 1994;18:25–31.

    CAS  PubMed  Google Scholar 

  13. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64:328–40.

    CAS  PubMed  Google Scholar 

  14. Bodey GP, Rodriguez V, Chang HY, Narboni G. Fever and infection in leukemic patients: a study of 494 consecutive patients. Cancer. 1978;41:1610–22.

    CAS  PubMed  Google Scholar 

  15. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med. 1995;332:901–6.

    CAS  PubMed  Google Scholar 

  16. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101:1644–55.

    CAS  PubMed  Google Scholar 

  17. Bosly A, Bron D, Van Hoof A, De Bock R, Berneman Z, Ferrant A, Kaufman L, Dauwe M, Verhoef G. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol. 2008;87:277–83.

    CAS  PubMed  Google Scholar 

  18. Bow EJ. Neutropenic fever syndromes in patients undergoing cytotoxic therapy for acute leukemia and myelodysplastic syndromes. Semin Hematol. 2009;46:259–68.

    CAS  PubMed  Google Scholar 

  19. Bow EJ, Kilpatrick MG, Scott BA, Clinch JJ, Cheang MS. Acute myeloid leukemia in Manitoba. The consequences of standard “7 + 3” remission-induction therapy followed by high dose cytarabine postremission consolidation for myelosuppression, infectious morbidity, and outcome. Cancer. 1994;74:52–60.

    CAS  PubMed  Google Scholar 

  20. Bow EJ, Loewen R, Cheang MS, Shore TB, Rubinger M, Schacter B. Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults. J Clin Oncol. 1997;15:2254–61.

    CAS  PubMed  Google Scholar 

  21. Bow EJ, Meddings JB. Intestinal mucosal dysfunction and infection during remission-induction therapy for acute myeloid leukaemia. Leukemia. 2006;20:2087–92.

    CAS  PubMed  Google Scholar 

  22. Bow EJ, Wngard JR, Bowden RA. Infectious complications in patients receiving cytotoxic therapy for acute leukemia: history, background and approaches to management. In: Management of infections in oncology patients. London: Martin Dunitz; 2003. p. 71–128.

    Google Scholar 

  23. Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D’Antonio D, Buelli M, Nosari AM, Cilloni D, Zuffa E, Cantaffa R, Specchia G, Amadori S, Fabbiano F, Deliliers GL, Lauria F, Foa R, Del FA. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005;353:977–87.

    CAS  PubMed  Google Scholar 

  24. Cherif H, Johansson E, Bjorkholm M, Kalin M. The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematologica. 2006;91(2):215–22.

    Google Scholar 

  25. Chirivella I, Bermejo B, Insa A, Perez-Fidalgo A, Magro A, Rosello S, Garcia-Garre E, Martin P, Bosch A, Lluch A. Impact of chemotherapy dose-related factors on survival in breast cancer patients treated with adjuvant anthracycline-based chemotherapy. J Clin Oncol (Meet Abstr). 2006;24:668.

    Google Scholar 

  26. Chrischilles E, Delgado DJ, Stolshek BS, Lawless G, Fridman M, Carter WB. Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin’s lymphoma. Cancer Control. 2002;9:203–11.

    PubMed  Google Scholar 

  27. Corey AL, Snyder S. Antibiotics in 30 minutes or less for febrile neutropenic patients: a quality control measure in a new hospital. J Pediatr Oncol Nurs. 2008;25:208–12.

    PubMed  Google Scholar 

  28. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100:228–37.

    PubMed  Google Scholar 

  29. Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, Stuart N, Rea D, Bower M, Fernando I, Huddart R, Gollins S, Stanley A. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med. 2005;353:988–98.

    CAS  PubMed  Google Scholar 

  30. Cullen MH, Billingham LJ, Gaunt CH, Steven NM. Rational selection of patients for antibacterial prophylaxis after chemotherapy. J Clin Oncol. 2007;25:4821–8.

    PubMed  Google Scholar 

  31. de Souza-Viana L, Serufo JC, da Costa Rocha MO, Costa RN, Duarte RC. Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer. 2008;16:841–6.

    PubMed  Google Scholar 

  32. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004;32:858–73.

    PubMed  Google Scholar 

  33. Doezema D, Lunt M, Tandberg D. Cerumen occlusion lowers infrared tympanic membrane temperature measurement. Acad Emerg Med. 1995;2:17–9.

    CAS  PubMed  Google Scholar 

  34. Dzarr AA, Kamal M, Baba AA. A comparison between infrared tympanic thermometry, oral and axilla with rectal thermometry in neutropenic adults. Eur J Oncol Nurs. 2009;13:250–4.

    PubMed  Google Scholar 

  35. Erickson RS, Meyer LT, Woo TM. Accuracy of chemical dot thermometers in critically ill adults and young children. Image J Nurs Sch. 1996;28:23–8.

    CAS  PubMed  Google Scholar 

  36. Farnell S, Maxwell L, Tan S, Rhodes A, Philips B. Temperature measurement: comparison of non-invasive methods used in adult critical care. J Clin Nurs. 2005;14:632–9.

    PubMed  Google Scholar 

  37. Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA. 2001;286:1754–8.

    CAS  PubMed  Google Scholar 

  38. Ferrer R, Artigas A, Levy MM, Blanco J, Gonzalez-Diaz G, Garnacho-Montero J, Ibanez J, Palencia E, Quintana M, de la Torre-Prados MV. Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain. JAMA. 2008;299:2294–303.

    CAS  PubMed  Google Scholar 

  39. Fisk J, Arcona S. Tympanic membrane vs. pulmonary artery thermometry. Nurs Manag. 2001;32(42):45–8.

    Google Scholar 

  40. Fossa SD, Kaye SB, Mead GM, Cullen M, de Wit R, Bodrogi I, van Groeningen CJ, De Mulder PH, Stenning S, Lallemand E, De Prijck L, Collette L. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol. 1998;16:716–24.

    CAS  PubMed  Google Scholar 

  41. Freifeld A. Guidelines for antimicrobials in neutropenic cancer patients. In: 45th Annual Meeting of the Infectious Diseases Society of America. San Diego: IDSA; 2007.

    Google Scholar 

  42. Freifeld A, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Roslton KV, Young JAH, Wingard JR. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e46–e93.

    Google Scholar 

  43. Fulbrook P. Core body temperature measurement: a comparison of axilla, tympanic membrane and pulmonary artery blood temperature. Intensive Crit Care Nurs. 1997;13:266–72.

    CAS  PubMed  Google Scholar 

  44. Gardner A, Mattiuzzi G, Faderl S, Borthakur G, Garcia-Manero G, Pierce S, Brandt M, Estey E. Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. J Clin Oncol. 2008;26:5684–8.

    PubMed  Google Scholar 

  45. Gayol Mdel C, Font A, Casas I, Estrada O, Dominguez MJ, Pedro-Botet ML. Usefulness of the MASCC scale in the management of neutropenic fever induced by chemotherapy in patients with solid neoplasm. Medicina clinica. 2009;133(8):296–9.

    Google Scholar 

  46. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med. 1984;100:345–51.

    Google Scholar 

  47. Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Spreafico C, Laffranchi A, Caraceni A, Martini C, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol. 1995;13:2688–99.

    CAS  PubMed  Google Scholar 

  48. Hosmer W, Malin J, Wong M. Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer. Support Care Cancer. 2011;19:333–41.

    PubMed Central  PubMed  Google Scholar 

  49. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KVI, Shenep JL, Young LS. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730–51.

    PubMed  Google Scholar 

  50. Immunocompromised Host S. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. J Infect Dis. 1990;161:397–401.

    Google Scholar 

  51. Innes H, Lim SL, Hall A, Chan SY, Bhalla N, Marshall E. Management of febrile neutropenia in solid tumours and lymphomas using the multinational association for supportive care in cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer. 2008;16(5):485–91.

    Google Scholar 

  52. Intragumtornchai T, Sutheesophon J, Sutcharitchan P, Swasdikul D. A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma. 2000;37:351–60.

    CAS  PubMed  Google Scholar 

  53. Jeddi R, Achour M, Amor RB, Aissaoui L, Bouteraa W, Kacem K, Lakhal RB, Abid HB, BelHadjAli Z, Turki A, Meddeb B. Factors associated with severe sepsis: prospective study of 94 neutropenic febrile episodes. Hematology. 2010;15:28–32.

    PubMed  Google Scholar 

  54. Jevon P, Jevon M. Using a tympanic thermometer. Nurs Times. 2001;97:43–4.

    Google Scholar 

  55. Jun HX, Zhixiang S, Chun W, Reksodiputro AH, Ranuhardy D, Tamura K, Matsumoto T, Lee DG, Purushotaman SV, Lim V, Ahmed A, Hussain Y, Chua M, Ong A, Liu CY, Hsueh PR, Lin SF, Liu YC, Suwangool P, Jootar S, Picazo JJ. Clinical guidelines for the management of cancer patients with neutropenia and unexplained fever. Int J Antimicrob Agents. 2005;26 Suppl 2:S128–32; discussion S133–40.

    CAS  PubMed  Google Scholar 

  56. Klastersky J, Ameye L, Maertens J, Georgala A, Muanza F, Aoun M, Ferrant A, Rapoport B, Rolston K, Paesmans M. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents. 2007;30 Suppl 1:S51–9.

    CAS  PubMed  Google Scholar 

  57. Klastersky J, Paesmans M, Georgala A, Muanza F, Plehiers B, Dubreucq L, Lalami Y, Aoun M, Barette M. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol. 2006;24:4129–34.

    CAS  PubMed  Google Scholar 

  58. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038–51.

    CAS  PubMed  Google Scholar 

  59. Klastersky J, Zinner SH, Calandra T, Gaya H, Glauser MP, Meunier F, Rossi M, Schimpff SC, Tattersall M, Viscoli C. Empiric antimicrobial therapy for febrile granulocytopenic cancer patients: lessons from four EORTC trials. Eur J Cancer Clin Oncol. 1988;24 Suppl 1:S35–45.

    PubMed  Google Scholar 

  60. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106:2258–66.

    PubMed  Google Scholar 

  61. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Cheang M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589–96.

    PubMed  Google Scholar 

  62. Leonard RC, Miles D, Thomas R, Nussey F. Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients. Br J Cancer. 2003;89:2062–8.

    CAS  PubMed Central  PubMed  Google Scholar 

  63. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. 2003;29:530–8.

    PubMed  Google Scholar 

  64. Link H, Bohme A, Cornely OA, Hoffken K, Kellner O, Kern WV, Mahlberg R, Maschmeyer G, Nowrousian MR, Ostermann H, Ruhnke M, Sezer O, Schiel X, Wilhelm M, Auner HW. Antimicrobial therapy of unexplained fever in neutropenic patients–guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol. 2003;82 Suppl 2:S105–17.

    CAS  PubMed  Google Scholar 

  65. Lutgens LC, Blijlevens NM, Deutz NE, Donnelly JP, Lambin P, De Pauw BE. Monitoring myeloablative therapy-induced small bowel toxicity by serum citrulline concentration: a comparison with sugar permeability tests. Cancer. 2005;103:191–9.

    PubMed  Google Scholar 

  66. Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study. J Clin Oncol. 2004;22:4302–11.

    CAS  PubMed  Google Scholar 

  67. Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist. 2005;10:427–37.

    PubMed  Google Scholar 

  68. Mackowiak PA, Bartlett JG, Bordon BC, et al. Concepts of fever: recent advances and lingering dogma. Clin Infect Dis. 1997;35:119–38.

    Google Scholar 

  69. Mackowiak PA, Wasserman SS. Physicians’ perceptions regarding body temperature in health and disease. South Med J. 1995;88:934–8.

    CAS  PubMed  Google Scholar 

  70. Mackowiak PA, Wasserman SS, Levine MM. A critical appraisal of 98.6 degrees F, the upper limit of the normal body temperature, and other legacies of Carl Reinhold August Wunderlich. JAMA. 1992;268:1578–80.

    CAS  PubMed  Google Scholar 

  71. Maher DW, Lieschke GJ, Green M, Bishop J, Stuart-Harris R, Wolf M, Sheridan WP, Kefford RF, Cebon J, Olver I, McKendrick J, Toner G, Bradstock K, Lieschke M, Cruickshank S, Tomita DK, Hoffman EW, Fox RM, Morstyn G. Filgrastim in patients with chemotherapy-induced febrile neutropenia – a double-blind, placebo-controlled trial. Ann Intern Med. 1994;121:492–501.

    CAS  PubMed  Google Scholar 

  72. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23:1638–52.

    CAS  PubMed  Google Scholar 

  73. Martin C, Brun-Buisson C, pour les Membres du Groupe de Travail (Annane D, CJ, Dhainaut JF, Gerbeaux P, Goldstein P, Hamza J, Leclerc F, Leconte P, Montravers P, Malledant Y, Orliaguet G, Payen D, Pourriat JL, Sadik A, Sollet JP, Vallet B) Prise en charge initiale des états septiques graves de l’adulte et de l’enfant. In: Conférence de consensus 2007, vol. http://www.sfmu.org/documents/consensus/Groupe%20Transversal%20Sepsis%20Fn.doc. 2007.

  74. Meropol NJ, Somer RA, Gutheil J, Pelley RJ, Modiano MR, Rowinsky EK, Rothenberg ML, Redding SW, Serdar CM, Yao B, Heard R, Rosen LS. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol. 2003;21:1452–8.

    CAS  PubMed  Google Scholar 

  75. Nucci M, Anaissie E. Revisiting the source of candidemia: skin or gut? Clin Infect Dis. 2001;33:1959–67.

    CAS  PubMed  Google Scholar 

  76. Nucci M, Spector N, Bueno AP, Solza C, Perecmanis T, Bacha PC, Pulcheri W. Risk factors and attributable mortality associated with superinfections in neutropenic patients with cancer. Clin Infect Dis. 1997;24:575–9.

    CAS  PubMed  Google Scholar 

  77. O’Toole S. Alternatives to mercury thermometers. Prof Nurs. 1997;12:783–6.

    Google Scholar 

  78. Oguz A, Karadeniz C, Ckitak EC, Cil V. Which one is a risk factor for chemotherapy-induced febrile neutropenia in childhood solid tumors: early lymphopenia or monocytopenia? Pediatr Hematol Oncol. 2006;23:143–51.

    PubMed  Google Scholar 

  79. Paesmans M, Klastersky J, Maertens J, Georgala A, Muanza F, Aoun M, Ferrant A, Rapoport B, Rolston K, Ameye L. Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter? Support Care Cancer. 2011;19:1001–8.

    PubMed  Google Scholar 

  80. Peacock JE, Herrington DA, Wade JC, Lazarus HM, Reed MD, Sinclair JW, Haverstock DC, Kowalsky SF, Hurd DD, Cushing DA, Harman CP, Donowitz GR. Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients. A randomized, double-blind trial. Ann Intern Med. 2002;137:77–87.

    CAS  PubMed  Google Scholar 

  81. Perrone J, Hollander JE, Datner EM. Emergency department evaluation of patients with fever and chemotherapy-induced neutropenia. J Emerg Med. 2004;27:115–9.

    PubMed  Google Scholar 

  82. Pettengell R, Bosly A, Szucs TD, Jackisch C, Leonard R, Paridaens R, Constenla M, Schwenkglenks M. Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. Br J Haematol. 2009;144:677–85.

    PubMed  Google Scholar 

  83. Pettengell R, Schwenkglenks M, Leonard R, Bosly A, Paridaens R, Constenla M, Szucs TD, Jackisch C. Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer. 2008;16(11):1299–309.

    PubMed  Google Scholar 

  84. Ray-Coquard I, Borg C, Bachelot T, Sebban C, Philip I, Clapisson G, Le Cesne A, Biron P, Chauvin F, Blay JY. Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer. 2003;88:181–6.

    CAS  PubMed Central  PubMed  Google Scholar 

  85. Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, Elting LS, Fox PC, Cooksley C, Sonis ST. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer. 2004;100:2026–46.

    PubMed  Google Scholar 

  86. Santolaya ME, Rabagliati R, Bidart T, Paya E, Guzman AM, Morales R, Braun S, Bronfman L, Ferres M, Flores C, Garcia P, Letelier LM, Puga B, Salgado C, Thompson L, Tordecilla J, Zubieta M. Consensus: rational approach towards the patient with cancer, fever and neutropenia. Rev Chil Infectol. 2005;22 Suppl 2:S79–113.

    Google Scholar 

  87. Schimpff SC, Gaya H, Klastersky J, Tattersall MH, Zinner SH. Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. The EORTC international antimicrobial therapy project group. J Infect Dis. 1978;137:14–29.

    CAS  PubMed  Google Scholar 

  88. Schimpff SC, Young VM, Greene WH, Vermeulen GD, Moody MR, Wiernik PH. Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens. Ann Intern Med. 1972;77:707–14.

    CAS  PubMed  Google Scholar 

  89. Schwenkglenks M, Jackisch C, Constenla M, Kerger JN, Paridaens R, Auerbach L, Bosly A, Pettengell R, Szucs TD, Leonard R. Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment. Support Care Cancer. 2006;14:901–9.

    PubMed  Google Scholar 

  90. Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med. 1975;135:715–9.

    CAS  PubMed  Google Scholar 

  91. Sickles EA, Young VM, Greene WH, Wiernik PH. Pneumonia in acute leukemia. Ann Intern Med. 1973;79:528–34.

    CAS  PubMed  Google Scholar 

  92. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187–205.

    CAS  PubMed  Google Scholar 

  93. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein EB. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100:1995–2025.

    PubMed  Google Scholar 

  94. Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J, Hayden V, Eilers J, Epstein JB, LeVeque FG, Miller C, Peterson DE, Schubert MM, Spijkervet FK, Horowitz M. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 2001;19:2201–5.

    CAS  PubMed  Google Scholar 

  95. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T, Shea T, Yanovich S, Hansen K, Noga S, McCarty J, LeMaistre CF, Sung EC, Blazar BR, Elhardt D, Chen MG, Emmanouilides C. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004;351:2590–8.

    CAS  PubMed  Google Scholar 

  96. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, Lee EJ, Moore JO, Powell BL, Schiffer CA. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med. 1995;332:1671–7.

    CAS  PubMed  Google Scholar 

  97. Talcott JA. Outpatient management of febrile neutropenia: should we change the standard of care? Oncologist. 1997;2:365–73.

    PubMed  Google Scholar 

  98. Talcott JA, Finberg R, Mayer RJ, Goldman L. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med. 1988;148:2561–8.

    CAS  PubMed  Google Scholar 

  99. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol. 1992;10:316–22.

    CAS  PubMed  Google Scholar 

  100. Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol. 1994;12:107–14.

    CAS  PubMed  Google Scholar 

  101. Tamura K. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group. Int J Antimicrob Agents. 2005;26 Suppl 2:S123–7.

    CAS  PubMed  Google Scholar 

  102. Timmer-Bonte JN, de Boo TM, Smit HJ, Biesma B, Wilschut FA, Cheragwandi SA, Termeer A, Hensing CA, Akkermans J, Adang EM, Bootsma GP, Tjan-Heijnen VC. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomized phase III study. J Clin Oncol. 2005;23:7974–84.

    CAS  PubMed  Google Scholar 

  103. Tjan-Heijnen VC, Postmus PE, Ardizzoni A, Manegold CH, Burghouts J, van Meerbeeck J, Gans S, Mollers M, Buchholz E, Biesma B, Legrand C, Debruyne C, Giaccone G. Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study. Ann Oncol. 2001;12:1359–68.

    CAS  PubMed  Google Scholar 

  104. Toussaint E, Bahel-Ball E, Vekemans M, Georgala A, Al-Hakak L, Paesmans M, Aoun M. Causes of fever in cancer patients (prospective study over 477 episodes). Support Care Cancer. 2006;14:763–9.

    CAS  PubMed  Google Scholar 

  105. Uys A, Rapoport BL, Anderson R. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer. 2004;12:555–60.

    PubMed  Google Scholar 

  106. Uys A, Rapoport BL, Fickl H, Meyer PW, Anderson R. Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1beta, -6, -8 and -10. Eur J Cancer Care (Engl). 2007;16:475–83.

    CAS  Google Scholar 

  107. Viscoli C, Bruzzi P, Castagnola E, Boni L, Calandra T, Gaya H, Meunier F, Feld R, Zinner S, Klastersky J, Glauser M, Glauser & Group, E.I.A.T.C.P. Factors associated with bacteremia in febrile, granulocytopenic cancer patients. Eur J Cancer. 1994;30A:430–7.

    CAS  PubMed  Google Scholar 

  108. von Minckwitz G, Schwenkglenks M, Skacel T, Lyman GH, Pousa AL, Bacon P, Easton V, Aapro MS. Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis. Eur J Cancer. 2009;45:608–17.

    Google Scholar 

  109. Voog E, Bienvenu J, Warzocha K, Moullet I, Dumontet C, Thieblemont C, Monneret G, Gutowski MC, Coiffier B, Salles G. Factors that predict chemotherapy-induced myelosuppression in lymphoma patients: role of the tumor necrosis factor ligand-receptor system. J Clin Oncol. 2000;18:325–31.

    CAS  PubMed  Google Scholar 

  110. Wardley AM, Jayson GC, Swindell R, Morgenstern GR, Chang J, Bloor R, Fraser CJ, Scarffe JH. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol. 2000;110:292–9.

    CAS  PubMed  Google Scholar 

  111. Wunderlich CA, Seguin E. Medical thermometry and human temperature. New York: William Wood & Co.; 1871.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Medical Microbiology and Infectious Diseases, and Internal Medicine, Sections of Infectious Diseases and Haematology/Oncology, The University of Manitoba, Winnipeg, MB, Canada

    Eric J. Bow

  2. Manitoba Blood and Marrow Transplant Programme, and Infection Control Services, CancerCare Manitoba, Winnipeg, MB, Canada

    Eric J. Bow

Authors
  1. Eric J. Bow
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric J. Bow .

Editor information

Editors and Affiliations

  1. Department of Hematology, Oncology and Palliative Care, Klinikum Ernst von Bergmann, Potsdam, Germany

    Georg Maschmeyer

  2. Department of Infectious Diseases, Infection Control and Employee Health, M.D. Anderson Cancer Center University of Texas, Houston, Texas, USA

    Kenneth V.I. Rolston

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Bow, E.J. (2015). The Diagnostic Approach to the Febrile Neutropenic Patient: Clinical Considerations. In: Maschmeyer, G., Rolston, K. (eds) Infections in Hematology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-44000-1_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-44000-1_6

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-43999-9

  • Online ISBN: 978-3-662-44000-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation